US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CV Sciences, Inc.

0.0762

-0.0018-2.33%

Volume:3.27M

Turnover:244.66K

Market Cap:14.04M

PE:-9.50

High:0.0865

Open:0.0778

Low:0.0650

Close:0.0780

52wk High:0.0961

52wk Low:0.0230

Shares:184.26M

Float Shares:184.26M

Volume Ratio:1.01

T/O Rate:1.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0080

EPS(LYR):0.0201

ROE:-79.25%

ROA:-4.86%

PB:9.12

PE(LYR):3.78

Loading ...

Overview Company News Filings

CV Sciences Reports Third Quarter Revenue of $3.3 Million

Cv Sciences Q3 Pretax Profit USD -382 Thousand

THOMSON REUTERS

CV Sciences Inc. to Release Third Quarter 2025 Results

CV Sciences Inc enters new 600000 secured loan agreement with institutional investor

CV Sciences Q2 Sales $3.620M Down From $3.954M YoY

CV Sciences Inc. Reports Q2 2025 Revenue of $3.6M, Operating Loss Narrows to $0.1M, Achieves Positive Adjusted EBITDA

Cv Sciences Q2 Operating Expenses USD 1.975 Million

THOMSON REUTERS

CV Sciences, Inc. To Announce Second Quarter 2025 Results

CV Sciences Inc. Conducted Annual Meeting Virtually

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CVSI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CVSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CVSI\",,,,,undefined,":{"symbol":"CVSI","market":"US","secType":"STK","nameCN":"CV Sciences, Inc.","latestPrice":0.07618,"timestamp":1771621200000,"preClose":0.078,"halted":0,"volume":3271637,"delay":15,"changeRate":-0.023333333333333362,"floatShares":184263663,"shares":184263663,"eps":-0.00802,"marketStatus":"Market Closed","change":-0.00182,"latestTime":"02-20 16:00:00 EST Delay","open":0.0778,"high":0.0865,"low":0.065,"amount":244662.1622000001,"amplitude":0.275641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00802,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.078,"volumeRatio":1.0090662571944755},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CVSI\",,,,,undefined,":{"symbol":"CVSI","floatShares":184263663,"roa":"-4.86%","roe":"-79.25%","lyrEps":0.020148,"volumeRatio":1.0090662571944755,"shares":184263663,"dividePrice":0,"high":0.0865,"amplitude":0.275641,"preClose":0.078,"low":0.065,"week52Low":0.023,"pbRate":"9.12","psRate":"0.98","week52High":0.096125,"institutionHeld":0,"latestPrice":0.07618,"eps":-0.00802,"divideRate":0,"volume":3271637,"delay":15,"ttmEps":-0.00802,"open":0.0778,"prevYearClose":0.0614,"prevWeekClose":0.0509,"prevMonthClose":0.0426,"prevQuarterClose":0.0614,"fiveDayClose":0.0423,"twentyDayClose":0.044,"sixtyDayClose":0.0285},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CVSI\",params:#limit:5,,,undefined,":[{"date":"2025-11-13","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763067600000,"name":null,"time":"Post Market","dateTimestamp":1763010000000,"actualEps":null},{"date":"2025-08-13","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755115200000,"name":null,"time":"Post Market","dateTimestamp":1755057600000,"actualEps":null},{"date":"2025-05-14","symbol":"CVSI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747252800000,"name":null,"time":"Post Market","dateTimestamp":1747195200000,"actualEps":null},{"market":"US","date":"2025-03-27","symbol":"CVSI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"","actualEps":null},{"date":"2024-11-14","symbol":"CVSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1731574800000,"name":null,"time":"Pre-Market","dateTimestamp":1731560400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CVSI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CVSI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CVSI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583116235","title":"CV Sciences Reports Third Quarter Revenue of $3.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583116235","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583116235?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:00","pubTimestamp":1763067626,"startTime":"0","endTime":"0","summary":"CV Sciences Inc. reported revenue of $3.3 million for the third quarter of 2025, down from $3.9 million in the same period of 2024 and $3.6 million in the second quarter of 2025. Gross margin was 48.5% for the third quarter of 2025, compared to 46.0% in the third quarter of 2024 and 50.9% in the previous quarter. The company ended the quarter with a cash balance of $0.4 million, compared to $0.5 million at the end of 2024. Adjusted EBITDA showed a loss of $0.1 million for the third quarter of 2025, compared to a loss of $0.1 million in the same period last year and a positive $0.1 million in the previous quarter. During the quarter, CV Sciences expanded its product offering with the launch of Ignite, a men's performance formula.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4rcy4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"gpt_icon":0},{"id":"2583611511","title":"Cv Sciences Q3 Pretax Profit USD -382 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2583611511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583611511?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:00","pubTimestamp":1763067601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX1D52FB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","CVSI"],"gpt_icon":0},{"id":"2582957389","title":"CV Sciences Inc. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582957389","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582957389?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:15","pubTimestamp":1762816556,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL80BVnG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"gpt_icon":0},{"id":"2574310022","title":"CV Sciences Inc enters new 600000 secured loan agreement with institutional investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2574310022","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574310022?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:06","pubTimestamp":1760130363,"startTime":"0","endTime":"0","summary":"CV Sciences, Inc. has entered into a new secured financing agreement with an institutional investor, issuing a promissory note with an original principal amount of $600,000. The transaction, which closed on October 7, 2025, involved an original issuance discount of $150,000 and an additional $150,000 payment related to a modification of a previous agreement, resulting in net proceeds of $300,000 for the company. The note, due on April 6, 2027, requires monthly repayments starting April 6, 2026, and is secured by all company and subsidiary assets, including intellectual property. No interest will accrue unless there is an event of default, and early repayment within six months offers an 8% discount on the outstanding balance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDLbZYY1H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","CVSI"],"gpt_icon":0},{"id":"2559896129","title":"CV Sciences Q2 Sales $3.620M Down From $3.954M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2559896129","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559896129?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:05","pubTimestamp":1755115530,"startTime":"0","endTime":"0","summary":"CV Sciences (OTC:CVSI) reported $3.620 million in sales this quarter. This is a 8.45 percent decrease over sales of $3.954 million the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47105736/cv-sciences-q2-sales-3-620m-down-from-3-954m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","CV"],"gpt_icon":0},{"id":"2559989554","title":"CV Sciences Inc. Reports Q2 2025 Revenue of $3.6M, Operating Loss Narrows to $0.1M, Achieves Positive Adjusted EBITDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2559989554","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559989554?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:00","pubTimestamp":1755115251,"startTime":"0","endTime":"0","summary":"CV Sciences, Inc. reported its financial results for the second quarter of 2025, revealing a decrease in sales to $3.6 million compared to $4.0 million in the same period of 2024. This represents an 8% decline, primarily attributed to lower sales volume, influenced by state regulatory pressures. The gross margin improved to 50.9% from 47.0% in the second quarter of 2024, marking the highest gross margin since the third quarter of 2019. The company reported an operating loss of $0.1 million, a significant improvement from the $0.6 million operating loss in the same quarter of the previous year, mainly due to reduced selling, general, and administrative expenses. CV Sciences achieved a positive adjusted EBITDA of $0.1 million, contrasting with a negative adjusted EBITDA of $6,000 in the prior year's second quarter. 39% of the net revenue for this quarter came from new products launched since January 1, 2023, with a total of 34 new products introduced during this period. The company antic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2xyFsv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI"],"gpt_icon":0},{"id":"2559989373","title":"Cv Sciences Q2 Operating Expenses USD 1.975 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559989373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559989373?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:00","pubTimestamp":1755115201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nPLX07237B:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","CVSI"],"gpt_icon":0},{"id":"2558572792","title":"CV Sciences, Inc. To Announce Second Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558572792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558572792?lang=en_us&edition=fundamental","pubTime":"2025-08-09 05:00","pubTimestamp":1754686827,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nNDL9hsrWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"gpt_icon":0},{"id":"2541292100","title":"CV Sciences Inc. Conducted Annual Meeting Virtually","url":"https://stock-news.laohu8.com/highlight/detail?id=2541292100","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541292100?lang=en_us&edition=fundamental","pubTime":"2025-06-05 18:01","pubTimestamp":1749117702,"startTime":"0","endTime":"0","summary":"CV Sciences Inc. held its 2025 Annual Meeting on June 2, 2025, in a virtual format. The company's stockholders elected three directors: Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle. Stockholders also ratified Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, it was approved that the advisory vote on executive compensation will occur every two years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CV Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL4SFG7z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVSI","BK4183"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}